|
CogniPlus Study assessing Cognitive performance plus Physical activity in patients with Relapsing-Remitting MS under treatment with Betaferon®
|
Ongoing
|
Betaferon
|
4
|
16036
|
King Fahad Hospital (Madinah), Security Forces Hospital (Riyadh), Aseer Central Hospital, King Khalid University Hospital (Riyadh), Al-Noor Specialist Hospital (Makkah), King Abdul Aziz Specialist hospital (Taif), King Fahad Specialist Hospital (Dammam)
|
|
International Registry to assess mEdical Practice withlOngitudinal obseRvation for Treatment of Heart Failure(REPORT-HF)
|
Ongoing
|
N/A
|
4
|
2401
|
King Fahad Specialist Hospital (Dammam)
|
|
A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer
|
Ongoing
|
LEE011 (Ribociclib)
|
3
|
CLEE011E2301
|
King Khalid University Hospital (Riyadh)_ King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
Phase IIIb, Randomized Multicentre Comparative Trial to Evaluate the Long Term Effectiveness & Safety of the use of Carbaglu® in Patients with Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA)
|
Ongoing
|
Carglumic acid
|
3
|
IIT-OE-2013-001
|
King Abdulaziz Medical City NG (Riyadh)_ King Fahad Medical City (Riyadh)
|
|
A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
|
Ongoing
|
Sorafenib
|
3
|
BAY43-9006/14295
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
A Randomized, Multi-Center Study to Evaluate Cardiovascular Outcomes With ITCA 650 in Patients Treated With Standard of Care for Type 2 Diabetes
|
Completed
|
ITCA 650
|
3
|
ITCA 650-CLP-107
|
King Abdulaziz Medical City NG (Jeddah)_ King Abdulaziz Hospital NG (Al Ahsa)
|
|
Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy and Safety of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Subjects With Congenital Fibrinogen Deficiency
|
Ongoing
|
Octafibrin
|
3
|
Forma 02
|
King Khalid University Hospital (Riyadh)
|
|
Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis
|
Ongoing
|
Purified Poloxamer 188
|
3
|
MST-188-01
|
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh), Maternity and Children's Hospital (Al Ahsa)_ King Fahad Medical City (Riyadh)_ King Abdulaziz University Hospital (Jeddah)
|
|
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)
|
Ongoing
|
ABT-450/r/ABT-267 ABT-333Ribavirin (RBV)
|
3b
|
M14-423
|
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Fahad Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer
|
Ongoing
|
Pertuzumab / Trastuzumab / Taxane
|
3b
|
MO28047
|
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah)
|
